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People with multiple sclerosis (PwMS) have reduced bone mineral density (BMD), but the causes are unclear. 
Some factors that may cause reduced BMD in PwMS have been understudied, including physical activity, 
inflammation, cortisol, symptomatic fatigue, and depression. The aim of this study was to investigate factors 
that may uniquely contribute to reduced BMD in PwMS as compared to people without MS. We hypothesized 
that physical activity would be the primary determinant of low BMD in PwMS, with additional contributions 
from inflammation and sympathetic nervous system activation. 
Methods 
We tested 23 PwMS (16 women; median EDSS: 2) and 22 control participants (16 women). BMD was measured 
from the femoral neck and lumbar spine with dual x-ray absorptiometry. Disability was measured with the 
Expanded Disability Status Scale, and functional capacity was measured with the Multiple Sclerosis Functional 
Composite. Questionnaires measured symptomatic fatigue and depression. A blood draw was used to measure 
calcium, phosphate, vitamin D, N-terminal telopeptide, osteopontin, and cytokine markers of inflammation. 
Physical activity was measured with accelerometry. Salivary cortisol and cardiac heart rate variability also were 
obtained. All outcome variables were compared between groups with independent samples t-tests. Variables 
that were different between groups and significantly correlated (Pearson product-moment) with femoral neck 
BMD, were included in a theoretical model to explain femoral neck BMD. The expected direction of relations in 
the theoretical model were developed based upon the results of previous research. A Bayesian path analysis was 
used to test the relations of predictive variables with femoral neck BMD and interrelations among predictive 
variables, as detailed in the theoretical model. 
Results 
PwMS had lower BMD at the femoral neck than controls (p = =0.04; mean difference: -0.09; 95% CI: -0.2, -0.004; 
Cohen's d = =0.65), and there was a smaller, statistically non-significant difference in BMD at the lumbar spine 
(p = =0.07; mean difference: -0.08; 95% CI: -0.17, 0.007; Cohen's d = =0.59). PwMS also had lower functional 
capacity (p ≤ 0.001; Cohen's d = =1.50), greater fatigue (p<0.001; Cohen's d = =1.88), greater depression 
(p<0.001; d = =1.31), and decreased physical activity (p = =0.03; Cohen's d = =0.62). Using path analysis to test 
our theoretical model, we found that disability (standardized estimate= -0.17), physical activity (standardized 
estimate=0.39), symptomatic fatigue (standardized estimate= -0.36), depression (standardized estimate= -0.30), 
and inflammatory markers (standardized estimate=0.27) explained 51% of the variance in femoral neck BMD. 
Inflammatory markers were also predictive of disability (standardized estimate=0.44) and physical activity 
(standardized estimate= -0.40). Symptomatic fatigue and depression were correlated (r = =0.64). 
Conclusion 
Physical activity, symptomatic fatigue, depression, disability, and inflammation all contributed independently to 
decreased femoral neck BMD in PWMS. Bone metabolism in PwMS is complex. Efforts to increase physical 
activity and address symptomatic fatigue and depression may improve bone mineral density in PwMS. Future 
research should investigate the mechanisms through which symptomatic fatigue and depression contribute to 
reduced BMD in PwMS. 
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Abreviation Definition 
25(OH)D 25-hydroxyvitamin D 
BDI beck depression inventory II 
BMD bone mineral density 
DIC deviance information criterion 
DXA dual energy x-ray absorptiometry 
EDSS expanded disability status scale 
EPA expected predictive accuracy 
FIS fatigue impact scale 
HRV heart rate variability 
IL-6 interleukin 6 
IL-10 interleukin 10 
LOO leave-one-out information criterion 
MCID minimal clinically important difference 
MDC minimal detectable change 
MHVH moderate, hard, and very hard 
MS multiple sclerosis 
MSFC multiple sclerosis functional composite 
NTX N-terminal telopeptide 
PASAT paced auditory serial addition test 
ppp posterior predictive p-values 
PSRF potential scale reduction factor 
PWMS people with multiple sclerosis 
SEM standard error of the mean 
sTNF-RII soluble receptors for tumor necrosis factor type II 
WAIC widely applicable information criterion 
 
1. Introduction 
Multiple sclerosis (MS) is an autoimmune disease of the central nervous system. People with MS (PwMS) 
experience impaired balance, coordination, strength, and vision (Compston and Coles, 2008). PwMS also have 
reduced bone mineral density (BMD) in multiple regions including the lumbar spine, femoral neck, and hip 
(Huang et al., 2015). These impairments increase the risk of falls and fractures and threaten independence and 
quality of life (Dong et al., 2015; Nilsagård et al., 2009). Therefore, it is important to identify factors contributing 
to reduced BMD in PwMS. 
Prior research on BMD in PwMS has primarily focused on the contributions of corticosteroids and 25-
hydroxyvitamin D [25(OH)D]. Corticosteroid use is recommended for acute treatment in PwMS (Smets et al., 
2017) but has been linked to increased risk of osteoporosis (van Staa et al., 2002). 25(OH)D levels are often low 
in PwMS and may lead to decreased calcium (Ca2+) absorption, increased bone resorption, and low BMD 
(Cosman et al., 1998; Nieves et al., 1994; Ozgocmen et al., 2005; Holick, 2007). However, findings related to both 
factors have been inconclusive. Several studies demonstrated that short-duration or chronic corticosteroid use 
does not reduce BMD in PwMS and may even improve BMD secondary to mobility improvements (Cosman et al., 
1998; Schwid et al., 1996; Olsson et al., 2015). Other studies found that corticosteroid use is associated with 
decreased BMD in PwMS (Nieves et al., 1994; Ozgocmen et al., 2005; Triantafyllou et al., 2012). Similarly, there 
is evidence that 25(OH)D is associated with either higher or lower BMD in PwMS (Cosman et al., 
1998; Nieves et al., 1994; Olsson et al., 2015; Triantafyllou et al., 2012). 
One consistent finding is that BMD is lower in PwMS with greater disability (Cosman et al., 1998; Nieves et al., 
1994; Schwid et al., 1996; Weinstock-Guttman et al., 2004; Pilutti and Motl, 2019). This relation may result from 
the mediating effects of disuse and decreased physical activity (Olsson et al., 2015; Batista et al., 2012). Physical 
activity is reduced in PwMS (Motl et al., 2005), which may decrease the mechanical stress imposed upon the 
skeletal system and lead to decreased BMD (Bielemann et al., 2013). Only one study has investigated the 
relation between physical activity and BMD in PwMS, and it is still unclear whether disability has an effect 
independent of physical activity (Mojtahedi et al., 2008). 
Other factors that may contribute to reduced BMD in PwMS have received limited investigation. MS is 
associated with inflammation, which can contribute to bone resorption (Amarasekara et al., 2015). Increased 
plasma cortisol levels in PwMS (Michelson et al., 1994) could negatively affect bone structure, as seen in 
hypercortisolism (Fassbender et al., 1998; Mancini et al., 2004). Finally, symptomatic fatigue and depression, 
affecting over 50% of PwMS, may indirectly lead to decreased BMD by contributing to lower physical activity 
(Siegert and Abernethy, 2005; Krupp, 2003). Depression also is associated with increased activation of the 
sympathetic nervous system, which stimulates bone resorption (Yirmiya et al., 2006). 
The purpose of this study was to investigate factors that uniquely contribute to reduced BMD in PwMS as 
compared to people without MS. We used path analysis to test a theoretical model explaining the inter-relations 
between these factors and BMD. We hypothesized that physical activity would be the primary determinant of 
low BMD in PwMS, with additional contributions from inflammation and sympathetic nervous system activation. 
2. Materials and methods 
2.1. Participants 
23 PwMS (16 women; 41±7 years; mean±SD) and 21 control participants (16 women; 39±8 years) were recruited 
through advertisements with the local chapter of the National Multiple Sclerosis Society and from a local 
neurologic clinic. Participants were 18–55 years old, were non-smokers, had no personal/family history of 
osteoporosis, did not use proton-pump inhibitors, and had no other major neurologic, metabolic, or 
cardiovascular diseases. Women were pre-menopausal with regular menstrual cycles. MS participants were 
ambulatory with an Expanded Disability Status Scale (EDSS) score ≤5, were not concurrently involved in a clinical 
drug trial, and had not received steroid treatments in the prior 3 months. Control participants were matched for 
age and sex at the group level. All participants provided written informed consent approved by the Marquette 
University Institutional Review Board. 
2.2. Procedures 
Across two visits separated by one week, participants completed: Visit 1: a bone mineral density scan, 
questionnaires of symptomatic fatigue and depression, and a blood draw; Visit 2: tests of functional capacity 
and an assessment of heart rate variability. Between visits, physical activity and late-night salivary cortisol were 
assessed. All data were collected over a 2-year span (2011–2013) between April and November because of 
seasonal variations in UVB radiation and vitamin D production (Holick, 1995). 
BMD was measured from the femoral neck and lumbar spine (L1-L4) with dual energy x-ray absorptiometry 
(DXA, Lunar Prodigy software version 11.4, GE Healthcare, Chicago, IL, USA). Z-scores were determined by 
normalizing to a sex- and age-matched population (norms from GE Healthcare). Measurements for all 
participants were performed by a single, trained member of the study team on the calibrated DXA scanner 
maintained to manufacturer specifications. Scans were reviewed by a rheumatologist, and regions of interest 
were adjusted if needed. 
EDSS was assessed by a neurologist as a measure of MS-related disability (Kurtzke, 1983). Global functional 
capacity was assessed with the MS Functional Composite (MSFC) comprised of the timed 25 foot walk, 9-hole 
peg test, and Paced Auditory Serial Addition Test (PASAT) (Fischer et al., 1999). Times/scores for the MSFC were 
transformed into z-scores based on a representative database of PwMS (Fischer et al., 2001). Symptomatic 
fatigue and its impact on function and quality of life were assessed with the Fatigue Impact Scale (FIS) 
(Fisk et al., 1994). Scores were determined for the entire FIS and three subscales: cognitive, physical, and 
psychosocial. Depressive symptoms were assessed with the Beck Depression Inventory II (BDI) (Beck et al., 
1996). 
An antecubital venous blood sample was obtained for measurements of plasma or serum levels of Ca2+, 
phosphate (PO4), 25(OH)D, N-terminal telopeptide (NTX), osteopontin, and cytokine-related markers of 
inflammation [interleukin 6 (IL-6), interleukin 10 (IL-10), and soluble receptors for tumor necrosis factor type II 
(sTNF-RII)]. IL-6 and sTNF-RII are considered pro-inflammatory, while IL-10 is considered an anti-inflammatory 
marker (Amarasekara et al., 2015). NTX was assayed as a marker of bone resorption (Clemens et al., 1997). 
Osteopontin is thought to promote osteoclast adhesion to bone matrix, along with other immune functions 
(Gravallese, 2003) and has been reported to be high in people with relapsing-remitting MS (Vogt et al., 2003). 
Osteopontin (Human Osteopontin Quantikine HS600B), IL-6 (Human IL-6 Quantikine D0ST00), IL-10 (Human IL-
10 Quantikine, D100B), and sTNF-RII (Human sTNF RII/TNFRSF1B Quantikine, DRT200) were measured by 
enzyme immunoassay per manufacturer instructions (R&D Systems, Minneapolis, MN, USA). Batched serum was 
sent to the Zablocki VA Medical Center clinical laboratory for Ca2+ and PO4 analysis. 25(OH)D was analyzed by 
chemiluminescent immunoassay (Diasorin LIAISON 25 OH Vitamin D TOTAL Assay, Saluggia, Italy) (Ersfeld et al., 
2004). A serum assay was used to obtain a quantitative measure of cross-linked NTX of type I collagen (Abbott 
Osteomark NTX Serum ELISA, Abbott Park, IL, USA) (Clemens et al., 1997). 
Heart rate variability (HRV) was obtained as an indicator of cardiac autonomic balance. (Anon et al., 2004) A 
three-lead electrocardiogram was obtained during 10-min of quiet supine rest. HRV was determined as the 
standard deviation of the R-R interval. Data were sampled at 2000 Hz (CED Power 1401, Cambridge Electronic 
Design, Milton, Cambridge, UK), and analyzed using Spike2 5.15 (CED). 
Cortisol was measured from saliva, in part as a marker of stress. Between experimental visits, participants used a 
synthetic collection swab (Salimetrics LLC, Carlsbad, CA, USA) to collect a saliva sample prior to sleep (~10:00 
PM). Cortisol is at the nadir of its circadian rhythm at night, and a measurement at this time can represent a 
single measure of average systemic cortisol (Raff et al., 1998). Salivary cortisol was measured with competitive 
enzyme-linked immunosorbent assay (#1–3002, Salimetrics LLC, Carlsbad, CA, USA) according to manufacturer 
directions. 
Participants wore accelerometers (GT1M, and GT3X set on GT1M mode; Actigraph, Pensacola, FL, USA) around 
the waist for 6 days during all waking hours except when bathing or swimming. Participants completed a daily 
activity log (e.g. exercise, transportation) to correlate with accelerometer outputs. Activity was sampled as raw 
acceleration units (counts) in 1-minute epochs. Using standard cutoffs (Freedson et al., 1998), activity was 
classified as sedentary (0 counts), light (≤1951 counts), moderate (1952–5724 counts), hard (5725–9498 counts), 
and very hard (≥9499 counts) based on the counts within each epoch. Average daily counts and minutes within 
each classification were calculated. Average daily counts and minutes for all activity combined was also 
calculated. Moderate, hard, and very hard (MHVH) minutes and counts were combined to represent strenuous 
activities. For ease of interpretation, average daily count values were divided by 1000. Accelerometers were 
independently tested for reliability in our laboratory (Wyrick et al., 2008). 
2.3. Statistical analysis 
Statistical analyses were performed with SPSS 23 (IBM, Armonk, NY, USA) with an alpha=0.05. Data are 
presented as mean±SD. All variables were compared between groups with independent samples t-tests (MS 
group as the reference). Proportion of participants with osteopenia or osteoporosis were compared between 
groups with chi-square analysis. Effect sizes were determined with Cohen's d, calculated as the mean difference 
divided by the pooled standard deviation. 
Variables that were different between groups and significantly correlated (Pearson product-moment) with 
femoral neck BMD were included in a post-hoc theoretical model to explain femoral neck BMD in PwMS. 
Variables that were not different between groups or not significantly correlated with femoral neck BMD were 
excluded because our small sample size limited the number of parameters. Furthermore, we wanted to identify 
factors that contribute to low BMD, specifically, or to a greater extent in PwMS. We reasoned that limiting 
factors included in the model to just those that differed between PwMS and controls would identify the factors 
most likely to account for differences in BMD between groups. A theoretical model and path analysis were only 
performed for femoral neck BMD because we did not find a statistically significant between group difference for 
lumbar BMD (post-hoc decision). 
We performed a Bayesian path analysis (Kline, 2005) in R (Team, 2008) using the package blavaan (Merkle and 
Rosseel, 2016), which estimates the model with the general Bayesian software JAGS (Plummer, 2003). Path 
analysis allowed us to test multiple relations between variables with multiple outcomes while conforming to a 
hypothesized model and accounting for relations with other variables of interest (Kline, 2005). Specifically, we 
tested the relations between predictive variables (EDSS, IL-6, physical activity, FIS, and BDI) and absolute (g/cm2) 
femoral neck BMD. The path analysis also tested the regressive relation of IL-6 with EDSS and physical activity 
and the correlation between FIS and BDI. Model priors for each predictive variable identified the expected 
relations between variables to limit the inferential range. Priors were determined using previously published 
literature (e.g. see Introduction). 
Convergence of the Markov chains was determined using the potential scale reduction factor (PSRF), i.e. 
univariate R-hat (Gelman and Rubin, 1992). We determined that the model converged when R-hat was lower 
than 1.10 for every parameter (Brooks and Gelman, 1998). The models were run by burn-in 22,000 iterations 
and keeping the last 7000 iterations from 3 chains to build the posterior distributions. The priors for the model 
were weakly informative, indicating that they were not intended to guide the parameters but provide 
information to delineate the most likely data space for the parameters. Means/intercepts have a prior 
μ~N(0,100); the standard deviations have a prior δ~half-cauchy(0,2.5); the regressions have a prior β~N(0,50); 
and the correlations have a prior ρ~U(-1,1). A model without constraints was compared to a model with 
constraints on whether the β was positive or negative (based on a theoretical model). These constraints were 
set by specifying the respective β prior as a truncated normal (e.g. β~N(0,50)T(0,)) and not allowing β to be 
above/below 0. We compared the models with the Bayes factor, leave-one-out information criterion (LOO), and 
widely applicable information criterion (WAIC) to evaluate which model fit the data better. (Vehtari et al., 2017; 
, Gelman et al., al. (2019); Kass , 1995; Raftery, 1993) 
3. Results 
There were no differences between the MS and control group for age, height, mass, or BMI. MS participants 
were 5 ± 5 years (range: 1–18) post-diagnosis and had a median EDSS score of 2 (range: 0–5). 20 people had a 
relapsing-remitting MS phenotype and 3 people had a progressive phenotype. MS participants reported greater 
depression (p<0.001; Cohen's d = =1.31) and symptomatic fatigue (p<0.001; Cohen's d = =1.88) than controls. 
Functional capacity (MSFC) was lower in the MS compared to control group (p ≤ 0.001; Cohen's d = =1.50). 
See Table 1. 
Table 1. Anthropometry, depression, symptomatic fatigue, and function.  
MS Control p Mean diff. 95% CI Cohen's d 
Age (yr) 41.0 (7.5) 39.3 (8.1) 0.46 1.8 -3.0, 6.5 0.23 
Height (m) 1.69 (0.10) 1.72 (0.10) 0.23 -0.04 - 0.10, 0.03 0.37 
Mass (kg) 73.4 (14.8) 73.1 (15.4) 0.95 0.3 -8.9, 9.5 0.02 
BMI (kg/m2) 25.6 (3.7) 24.5 (4.0) 0.32 1.2 -1.2, 3.5 0.31 
BDI 10.6 (7.3) 3.2 (3.4) <0.001* 7.4 3.9, 10.9 1.31 
 FIS (total) 60.6 (39.9) 5.9 (10.4) <0.001* 54.7 36.6, 72.8 1.88 
  FIS (cognitive) 16.5 (11.3) 2.0 (4.1) <0.001* 14.6 9.3, 19.9 1.72 
   FIS (physical) 16.0 (11.0) 1.3 (2.0) <0.001* 14.8 9.8, 19.7 1.86 
FIS (social) 28.0 (18.9) 2.7 (5.0) <0.001* 25.4 16.8, 33.9 1.84 
MSFC (Z-score) 0.2 (0.6) 0.9 (0.3) <0.001* -0.7 -1.0, -0.4 1.50 
  25 ft. walk (s) 5.5 (3.9) 3.7 (0.5) 0.04* 1.8 0.07, 3.6 0.65 
 9-hole peg test(s) 21.6 (4.9) 17.7 (1.9) 0.002* 3.9 1.6, 6.2 1.05 
PASAT (#correct) 44.0 (12.0) 55.1 (4.7) <0.001* -11.0 -16.7, -5.3 1.22 
MS and control groups differed in depression, symptomatic fatigue, and functional capacity. 9-hole peg test is 
presented as the mean of dominant and non-dominant hand trials. BDI: Beck Depression Inventory; BMI: body 
mass index; FIS: Fatigue Impact Scale; MSFC: Multiple Sclerosis Functional Composite; PASAT: Paced Auditory 
Serial Addition Test. For all comparisons, the MS group was the reference group. Values are mean (SD). Mean 
difference values and the 95% confidence interval around this measure are presented. Cohen's d was calculated 
as the mean difference divided by the pooled standard deviation. 
⁎ p<0.05. 
 
At the femoral neck, PwMS had lower absolute BMD [0.98 (0.14) vs. 1.06 (0.14) g/cm2; p = =0.04; Mean 
difference: -0.09; 95% CI: -0.2, -0.004; Cohen's d = =0.65] and Z-scores [-0.21 (0.97) vs. 0.40 (0.92); p = =0.04; 
Mean difference: -0.6; 95% CI: -1.2, -0.04; Cohen's d = =0.67] than controls. At the lumbar spine, absolute BMD 
[1.17 (0.13) vs. 1.25 (0.14) g/cm2; p = =0.07; Mean difference: -0.08; 95% CI: -0.2, 0.007; Cohen's d = =0.59] and 
Z-scores [-0.18 (1.00) vs. 0.33 (1.10); p = =0.13; Mean difference: -0.5; 95% CI: -1.2, 0.2; Cohen's d = =0.49] were 
lower in PwMS, although statistically non-significant. Lumbar spine measurements were excluded from 2 PwMS 
and 1 control because of metal rods in the lumbar region. 
Of the inflammatory or bone metabolism markers, IL-6 and sTNF-RII were greater (p ≤ 0.009; Cohen's d ≥ 0.85) 
and Ca2+and PO4 levels were lower in PwMS compared to controls (p ≤ 0.03; Cohen's d ≥ 0.74). However, Ca2+and 
PO4 were within lab reference ranges limits (8.5–10.1 mg/dL and 2.5–4.9 mg/dL, respectively). There was no 
difference in salivary cortisol, HRV, or 25(OH)D between groups. Of note, at least 15 (65%) participants in the MS 
group and 9 (43%) participants in the control group self-reported at least some level of 25(OH)D 
supplementation. Total physical activity, moderate activity, and MHVH counts were all lower in PwMS compared 
to controls (p ≤ 0.03; Cohen's d ≥ 0.62). Minutes of moderate activity were also lower in PwMS compared to 
controls (p = =0.01; Cohen's d = =0.81), and there was a trend for minutes of MHVH activity to be lower in PwMS 
compared to controls (p = =0.07; Cohen's d = =0.75). See Table 2. 
Table 2. Potential physiological determinants of bone mineral density.  
MS Control p Mean diff. 95% CI Cohen's d 
Ca2+ (mg/dl) 9.25 (0.36) 9.52 (0.40) 0.03* -0.28 -0.52, -0.03 0.74 
PO4 (mg/dl) 3.35 (0.44) 3.72 (0.50) 0.02* -0.38 -0.68, -0.07 0.82 
25(OH)D (ng/ml) 38.7 (13.9) 32.9 (9.8) 0.12 5.8 -1.6, 13.2 0.49 
NTX (nM) 13.8 (2.7) 12.5 (4.2) 0.22 1.3 -0.8, 3.4 0.39 
Osteopontin (ng/ml) 57.0 (15.9) 56.3 (12.5) 0.88 0.8 -8.9, 10.5 0.05 
IL-10 (pg/ml) 1.40 (1.40) 0.90 (0.85) 0.30 0.50 -0.47, 1.46 0.43 
IL-6 (pg/ml) 1.60 (0.90) 0.96 (0.59) 0.009* 0.64 0.17, 1.11 0.85 
sTNF-RII (pg/ml) 3452 (651) 2880 (428) 0.001* 572 233, 910 1.05 
HRV (ms) 0.05 (0.02) 0.05 (0.02) 0.32 -0.006 -0.02, 0.006 0.32 
Cortisol (ug/ml) 0.09 (0.07) 0.11 (0.15) 0.56 -0.02 -0.09, 0.05 0.18 
Physical activity        
MS Control p Mean diff. 95%% CI Cohen's d 
Total (counts/1000) 263.2 (139.3) 346.6 (135.4) 0.03* -83.6 -165.8, -0.4 0.62 
Sedentary (counts/1000) 6.5 (1.6) 7.0 (1.7) 0.30 -0.5 -1.5, 0.5 0.34 
(minutes) 1102.6 (82.8) 1100.8 (82.8) 0.95 1.8 -53.5, 57.1 0.02 
Light (counts/1000) 160.7 (55.8) 173.1 (53.3) 0.46 -12.4 -46.1, 21.4 0.09 
(minutes) 299.3 (82.1) 288.2 (77.6) 0.65 11.2 -38.2, 60.6 0.14 
Moderate (counts/1000) 51.2 (41.9) 106.6 (80.6) 0.006* -55.4 -94.2, -16.6 0.83 
(minutes) 18.9 (13.2) 34.2 (24.7) 0.01* -15.3 -27.3, -3.3 0.81 
Hard (counts/1000) 17.6 (33.6) 31.2 (41.4) 0.24 -13.6 -36.7, 9.5 0.38 
(minutes) 3.0 (5.3) 4.3 (5.5) 0.41 -1.4 -4.7, 2.0 0.32 
Very hard (counts/1000) 2.9 (10.0) 24.5 (71.7) 0.16 -21.6 -52.1, 8.9 0.20 
(minutes) 1.0 (4.4) 1.3 (3.5) 0.80 -0.3 -2.8, 2.1 0.11 
MHVH (counts/1000) 71.7 (62.5) 162.3 (147.5) 0.01* -90.6 -158.7, -22.4 0.64 
(minutes) 22.8 (18.1) 39.8 (28.9) 0.07 -16.0 -33.2, 1.2 0.75 
Calcium and phosphate were lower and markers of pro-inflammation were higher in PwMS than in controls. 
Physical activity measures are shown in the bottom half of the table. For physical activity, total, moderate, and 
MHVH counts were lower in PwMS than in controls. For ease of interpretation, average daily count values for 
physical activity were divided by 1000. 25(OH)D: 25-hydroxyvitamin D; Ca2+: calcium; HRV: heart rate variability; 
IL-6: interleukin 6; IL-10: interleukin 10; NTX: N-terminal telopeptide; PO4: phosphate; sTNF-RII: soluble 
receptors for tumor necrosis factor type II. For all comparisons, the MS group was the reference group. Values 
are mean (SD). Mean difference values and the 95% confidence interval around this measure are presented. 
Cohen's d was calculated as the mean difference divided by the pooled standard deviation. 
⁎p<0.05. 
 
3.1. Path analysis 
A theoretical model (Fig. 1) was developed to explain femoral neck BMD but not lumbar BMD, because we did 
not detect statistically significant group differences at this latter site. Variables that rejected the null hypothesis 
of equality between the MS and control group and correlated with femoral neck BMD were included in the 
model: disability (EDSS: r=-0.49, p = =0.02), depression (BDI: r=-0.49, p = =0.02), symptomatic fatigue (FIS 
total: r=-0.65, p = =0.001), and physical activity (total counts: r = =0.48, p = =0.02). The theoretical relationships 
between these variables and femoral neck BMD were developed based on previously published literature. None 
of the other variables that were different between the MS and control group were correlated with femoral neck 
BMD (p ≥ 0.13). Total physical activity was used in the model because it had a larger bivariate correlation with 
femoral neck BMD than other physical activity variables. IL-6 was included in the model even though it was not 
correlated with femoral neck BMD because it was correlated with disability (r = =0.44, p = =0.04), and we had 
apriori expected it to have an independent impact on BMD and physical activity. Finally, we included a 
correlation term between depression and symptomatic fatigue (Fassbender et al., 1998). 
 
Fig. 1. Theoretical model. Solid lines show expected regressions predicting BMD of the femoral neck, EDSS, and 
physical activity. Dashed lines show expected correlations. Gray lines represent predicted positive relationships, 
while black line represent predicted negative relationships. BDI: Beck Depression Inventory; BMD: bone mineral 
density; EDSS: Expanded Disability Status Scale; FIS: Fatigue Impact Scale; IL-6: interleukin 6. 
 
Symptomatic fatigue and physical activity scores had large variances compared to other variables, so they were 
transformed to z-scores. The unconstrained model (not shown) had an overall good fit (posterior predictive p-
values (ppp)=0.11, deviance information criterion (DIC) =382.0, LOO=388.6, WAIC=385.6) and provided a good 
predictive model for BMD at the femoral neck (R2=0.47) and good predictions of EDSS (R2=0.18) and physical 
activity (R2=0.15) with IL-6 as a predictor. The constrained model (Table 3) included weakly informative 
constraints (priors) for negative relationships of depression, symptomatic fatigue, and EDSS and a positive 
relationship of physical activity with BMD. The relationship between IL-6 and EDSS was constrained to be 
positive, and the relationship between IL-6 and physical activity was constrained to be negative. The constrained 
model performed better than the unconstrained model but performed even better when the relationship 
between IL-6 and BMD was unconstrained. This final, partially constrained model had an overall good fit 
(ppp=0.14, DIC=378.9, LOO=384.5, WAIC=382.2) and provided a good predictive model for BMD at the femoral 
neck (R2=0.51) and good predictions of EDSS (R2=0.19) and physical activity (R2=0.16) with IL-6 as a predictor. 
The similarity between the constrained and unconstrained model suggests that our theoretical model largely 
matched the actual results. See Fig. 2 and Table 3 for final, partially constrained model with estimate 
parameters. Table 4 shows the standard error of the mean (SEM) for each predictive variable and how much 
change in femoral neck BMD would be associated with a 1 SEM change. Generally, a ± 2% change in BMD is 
considered clinically meaningful. At the femoral neck in PwMS, this translates to 0.0196 g/cm2. 
Table 3. Partially constrained model parameters. 
Parameter Mean estimate (SD) 95% CI Standardized estimate 
Direct effects on femoral neck BMD    
BDI → BMD -0.006 (0.003) -0.011, 0 -0.30 
FIS → BMD -0.001 (0.001) -0.002, 0 -0.36 
EDSS → BMD -0.021 (0.017) -0.053, 0 -0.17 
PA → BMD 0.055 (0.025) 0.005, 0.101 0.39 
IL-6 → BMD 0.043 (0.029) -0.013, 0.100 0.27 
Other parameters in the model    
IL-6 → EDSS 0.571 (0.253) 0.054, 1.032 0.44 
IL-6 → PA -0.458 (0.221) -0.850, -0.013 -0.40 
BDI ↔ FIS (covariance) 4.440 (1.939) 1.270, 8.615 0.64 
Indirect effects on femoral neck BMD    
IL-6 → EDSS → BMD -0.119 (0.02) -0.37, 0.048 -0.07 
IL-6 → PA → BMD -0.028 (0.02) -0.071, 0.008 -0.16 
 
For each parameter, the predictive variable is before the arrow, and the predicted variable is after the arrow. A 
one-way arrow represents a regression parameter while a two-way arrow represents a correlation parameter. 
The mean estimate shows the unstandardized estimate; every 1 unit increase in the predictive variable yields 
the estimated change in the predicted variable. However, for PA and FIS, every 1 SD increase in the predictive 
variable yields the estimated change in the predicted variable. Standardized estimates show the SD change in 
the predicted variable for every 1 SD increase in the predictive variable. BDI: Beck Depression Inventory; BMD: 
bone mineral density in g/cm2; CI = Bayesian Credible Interval; EDSS: Expanded Disability Status Scale; FIS: 
Fatigue Impact Scale; IL-6: interleukin 6; PA: physical activity. 
 
Fig. 2. Final, partially constrained model with parameter estimates. Solid lines show regression parameters 
predicting BMD of the femoral neck, EDSS, and physical activity. Dashed lines show correlation parameters. Gray 
lines represent positive relationships, while black line represent negative relationships. R2 values are shown for 
regression models and represent the variance of the predicted variable (BMD, EDSS, or physical activity) 
explained by all the predicted variables included in the model. r values are shown for correlations. BDI: Beck 
Depression Inventory; BMD: bone mineral density; EDSS: Expanded Disability Status Scale; FIS: Fatigue Impact 
Scale; IL-6: interleukin 6. 
 
Table 4. Change in BMD based upon β values. 
Parameter SEM ∆ in BMD MCID or MDC ∆ in BMD 
BDI → BMD 1.5 points -0.009 g/cm2 1.9 points -0.011 
FIS → BMD 8.3 points -0.008 g/cm2 11.7 points -0.012 
EDSS → BMD 0.25 points -0.005 g/cm2 0.5 points -0.010 
PA → BMD 29,000 counts 0.011 g/cm2 
  
IL-6 → BMD 0.19 pg/mL 0.008 g/cm2 
  
 
Change in femoral neck BMD is shown for a 1 standard error of the mean (SEM) change in each predictive 
variable. For example, a 1.5-point increase in BDI is associated with a 0.009 g/cm2 decrease in femoral neck 
BMD. The change in femoral neck BMD is also shown for a change in each predictive variable (BDI, FIS, and EDSS) 
that meets the minimal clinically important difference (MCID) or minimal detectable change (MDC) levels. For 
example, the MCID for FIS is 11.7 points (19.3% of baseline), and a change of this magnitude is associated with a 
0.012 g/cm2 decrease in femoral neck BMD. Note that for PA and FIS, β values (Table 3) represented a 1 SD 
change in the predictive variable. Generally, a ± 2% change in BMD is considered clinically meaningful. At the 
femoral neck in PwMS, this translates to 0.0196 g/cm2. BDI: Beck Depression Inventory; BMD: bone mineral 
density; EDSS: Expanded Disability Status Scale; FIS: Fatigue Impact Scale; IL-6: interleukin 6; PA: physical 
activity. 
We compared the unconstrained and partially constrained models with Bayes Factor. The resulting value of 11.5 
indicated that the partially constrained model fit the data 11 times better than the unconstrained model. We 
also compared the models with LOO and WAIC, which yielded the expected predictive accuracy (EPA). The 
difference in EPA for LOO was 2.04 (SE=0.829), which represents a difference of 2.46 standard errors. The 
difference in EPA for WAIC was 1.67 (SE=0.727), which represents a difference of 2.29 standard errors. These 
EPA differences also indicated that the partially constrained model fit the data better than the unconstrained 
model. 
4. Discussion 
In this study, we found that BMD at the femoral neck was decreased in PwMS compared to healthy controls. 
BMD at the lumbar spine was also decreased in PwMS, but statistically non-significant. Path analysis showed 
that physical activity, depression, symptomatic fatigue, disability, and IL-6 all contributed independently to BMD 
in PwMS within a theoretical framework. Together, these factors explained 51% of the variance in BMD, with the 
strongest contributions from physical activity, depression, and symptomatic fatigue. Below, we discuss the 
implications of these findings. 
Physical activity was decreased in PwMS compared to controls, as found previously (Motl et al., 2005), with 
most of the difference in moderate or higher physical activity. This is of interest because current physical activity 
recommendations for PwMS stress the importance of moderate intensity activity (American College of Sports 
Medicine. 2014). Our results suggest that lower physical activity affects BMD in this population; decreased 
physical activity was associated with decreased BMD at the femoral neck. The only other study that has 
evaluated the relation between physical activity and BMD in PwMS found an association between lower physical 
activity and lower femoral BMD in women, but intensity was not quantified (Mojtahedi et al., 2008). An 
association between physical activity and BMD in PwMS is consistent with a similar relation found in adults 
without MS (Bielemann et al., 2013). For our study, we used standard intensity cutoffs for physical activity 
(Freedson et al., 1998). Activity cutoffs for PwMS may not be the same as for those without MS and may 
underestimate activity intensity (Agiovlasitis and Motl, 2014). Nevertheless, our results suggest that an increase 
in physical activity of 29,000 accelerometer counts per day (~15 min of moderate physical activity) is associated 
with an increased femoral neck BMD of 0.01 g/cm2. Thus, increased physical activity may improve BMD in 
PwMS. Interestingly, BMD in the lumbar spine of PwMS was not statistically different from controls. This finding 
suggests that sitting may provide enough lumbar postural loading to partially maintain BMD, as seen in people 
with spinal cord injury (Leslie and Nance, 1993). 
We found that depression and symptomatic fatigue independently contributed to decreased BMD. In addition, 
greater symptomatic fatigue was correlated with depression which is consistent with symptomatic fatigue and 
depression being interrelated but independent constructs (Krupp, 2003; Greeke et al., 2017). Both depression 
and symptomatic fatigue contributed to decreased BMD independently of physical activity. Prior work suggests 
that depression is associated with decreased BMD in non-MS populations and that this relation can also be 
independent of physical activity (Bab and Yirmiya, 2010). Mechanistically, depression may increase activation of 
the sympathetic nervous system, or vice versa, stimulating bone resorption (Yirmiya et al., 2006; Cherruau et al., 
1999). However, our measure of cardiac sympathetic balance (HRV) was not different between groups nor was it 
associated with depression or BMD. Depression may contribute to decreased BMD through other mechanisms, 
or cardiac HRV may be an insufficient measure of overall sympathetic activation or autonomic balance. 
Alternatively, altered sympathetic activity may be better revealed during tests of reactivity instead of at rest. 
Furthermore, an informal assessment suggests that a large portion of our sample used medications (such as 
antidepressants) that may have skewed sympathetic balance or otherwise affected BMD. Lack of group 
difference in HRV is somewhat consistent with lack of group difference in late-night salivary cortisol whereas 
both could indicate basal “stress” levels. Immune dysregulation may be associated with depression and bone 
density (Cizza et al., 2009), but IL-6 was not related to depression in our study. Altered endocrine function has 
also been hypothesized to mediate the relationship between depression and bone density (Cizza et al., 2009), 
but our data provide no insight into this other than that our subjects seemed to be 25(OH)D replete. 
The mechanism by which symptomatic fatigue is related to decreased BMD in PwMS is also unclear, but 
cardiovascular autonomic impairment has been suggested to result in decreased bone density and symptomatic 
fatigue in PwMS (Sternberg, 2018). Further, alterations in sympathetic nervous system activation could be a 
shared mechanism in the associations between symptomatic fatigue, bone density, and depression, although 
the caveats discussed above must still be considered. 
Corresponding with numerous other studies, we found that PwMS with greater disability (i.e., EDSS) had lower 
BMD (Cosman et al., 1998; Nieves et al., 1994; Olsson et al., 2015; Weinstock-Guttman et al., 2004; Pilutti and 
Motl, 2019). Many investigators have suggested that the relationship between disability and BMD is mediated 
by physical activity (Olsson et al., 2015; Batista et al., 2012). However, in our study, EDSS had an independent 
contribution to BMD and was not associated with physical activity. This finding suggests that some aspect of the 
disease process decreases BMD independent of its effect on physical activity or other variables in the theoretical 
model. Like in MS, decreased BMD has been reported in rheumatoid arthritis, autoimmune thyroid disease, and 
other autoimmune disorders, pointing toward a shared autoimmune mechanism not elucidated by our findings 
(Iseme et al., 2017). 
Inflammation, as indicated by IL-6, was the only factor related to BMD that differed from our theoretical model. 
Previous work has suggested that increased inflammation is associated with decreased BMD 
(Amarasekara et al., 2015). However, we found that increased inflammation was associated with greater BMD at 
the femoral neck. This could be related to the effects of corticosteroid use whereby individuals using 
corticosteroids had lower inflammation, but also lower BMD. Participants in this study were excluded if they had 
used corticosteroids in the previous 3 months, but we did not assess historical use of corticosteroids. While IL-6 
was associated independently with greater BMD in our model, it also was associated with lower physical activity 
and greater disability. As a result, the total or net effect of IL-6 to BMD was close to zero (standardized estimate 
of the total effect=0.04), which is consistent with our finding that there was no significant bivariate correlation 
between IL-6 and femoral BMD (r=-0.04, p = =0.86). IL-6 is a pleotropic cytokine with both direct signal pathways 
and trans pathways with soluble receptors (Mihara et al., 2012). The actions of IL-6 are complex and can be 
contradictory; while IL-6 is usually thought to be osteoclastic, its actions can both stimulate or inhibit bone 
resorption (Mihara et al., 2012; Yoshitake et al., 2008). For example, IL-6 deficiency has been associated with 
bone resorption in some animal models (Balto et al., 2001). Furthermore, IL-6 is just one of several markers of 
inflammation, and our results found both greater pro-inflammatory markers (IL-6 and sTNF-RII) and greater anti-
inflammatory markers (IL-10). However, these other factors were not correlated with femoral neck BMD. 
Lack of difference between PwMS and controls does not negate the importance of factors known to influence 
BMD. Rather, our study highlights factors that may specifically explain differences in BMD between PwMS and 
controls. For example, 25(OH)D is important for bone metabolism (Holick, 2007), but was not different between 
the MS and control groups. Contrary to reports of low 25(OH)D in PwMS (Nieves et al., 1994), 25(OH)D was 
replete in both the MS and control group in this study (Holick and Vitamin, 2009). At least 15 participants (65%) 
in the MS group reported regularly taking some form of 25(OH)D supplementation. That 25(OH)D was replete 
and so many PwMS were supplementing may speak to the beneficial widespread attention to 25(OH)D in PwMS 
and their medical team. However, some recommendations suggest that >40 ng/mL is safe and optimal, meaning 
that additional supplementation may be beneficial for both people with and without MS (Bischoff-Ferrari et al., 
2006). 
One limitation of this study is that we restricted our theoretical model to include only variables that were 
different between groups and correlated with femoral neck BMD. We constrained the number of relationships 
reflected in our theoretical model because of limited sample size. Furthermore, we reasoned that the criteria 
imposed were likely to yield the most relevant factors for decreased BMD in PwMS as compared to people 
without MS. Other factors related to BMD might not have been captured because of this limitation, and their 
contribution to BMD in PwMS and/or people without MS should not be minimized. The role of vitamin D 
supplementation, chronic corticosteroid use, and different disease-modifying treatments were not explored and 
likely impact BMD, inflammation, and other factors in PwMS. In the future, larger sample sizes may allow a more 
complete evaluation of the factors contributing to decreased BMD and interrelations among these factors. 
Another limitation is that our study was cross-sectional. Any interpretations from our findings must be tempered 
by the limitation that it takes time (months to years) to build BMD, and our findings may not be reflective of 
prior lifestyle. Finally, this study was performed in PwMS with mild disability (median EDSS of 2), and the results 
may not extend to individuals with greater disability (i.e. EDSS). 
5. Conclusions 
Our study illustrates the complexity of bone metabolism in PwMS while stressing the importance of physical 
activity to maintain BMD. This importance cannot be overstated. Physical activity is safe and efficacious for 
persons with MS (Latimer-Cheung et al., 2013) and an inexpensive, non-pharmacological intervention to 
improve BMD and potentially decrease fracture risk. 
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